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four of 6 PNR cases. We think that, the deﬁnitions in the guidelines
should be revised with real- life experiences. In our opinion, PNR
shouldbe evaluated in the sixthmonthof treatment insteadof third
month.
http://dx.doi.org/10.1016/j.ijid.2014.03.1334
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Background: Lamivudine therapy in chronic hepatitis B (CHB)
treatment is not encouraged because of its lower resistance bar-
rier. In this study, we aimed to investigate the long-term efﬁcacy
of lamivudine treatment in HBeAg negative CHB patients.
Methods & Materials: This retrospective study is conducted in
three different tertiary care hospitals. Virological response (VR) is
deﬁned as undetectable HBV DNA by a sensitive PCR assay during
therapy. Partial virological response (PVR) is deﬁned as a decrease
in HBV DNA of more than 1 log10 IU/ml but detectable HBV DNA
after at least 6 months of therapy in compliant patients. Virologi-
cal breakthrough also called as relapse is deﬁned as a conﬁrmed
increase in HBV DNA level of more than 1 log10 IU/ml compared to
the lowest value of HBV DNA level on therapy.
Results: A total of 145 patients (57,9% male) were evaluated.
Theirmean agewas 44,6 years and 23 (15,9%) of themwere treated
with interferons previously. The median value of the ISHAK histo-
logical activity index (HAI) and ﬁbrosis were 6 (range: 2-16) and 1
(range: 1-5). Themeanvalue of ALT, AST, andHBVDNAwere57U/L,
42 U/L and 1.189.806 IU/mL, respectively. Treatment of ﬁfty-three
(36,6%) patientswas switched tomore potent drugs due to PVR (29;
20%) or relapse (24; 16,6%). Relapse was observed between 13 and
36 months in majority of relapsers (12 cases in 13 to 24 months
and 8 cases in 25 to 36 months). VR was observed in 92 (63,4%) and
their median time on lamivudine therapy was 34,5 months (range:
6-78 months). Baseline characteristics of virologic responders and
switched group were shown in Table 1.
Conclusion: Our results showed that more than 60% patients
maintain viral suppression more than thirty months. Lamivudine
can still be a reliable drug especially in low-income countries
because of its low cost. However, lamivudine should be used with
more caution in patients who have low thrombocyte and high HAI,
ﬁbrosis, ALT, and AST levels.
http://dx.doi.org/10.1016/j.ijid.2014.03.1335
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Background: Acute respiratory tract infections (ARTIs) are a
signiﬁcant cause of morbidity and account for a major percent-
age of mortality in early childhood worldwide. Viral infections are
responsible for most respiratory infections.
Methods & Materials: Nasopharyngeal aspirates (NPA) speci-
mens were collected from 1800 pediatric patients who suspected
acute respiratory infection in Southern China Samples were
screened for 21 kinds of respiratory viruses by multiplex reverse
transcription-PCR(RT-PCR) with a GenomeLab Gene Expression
Proﬁler (GeXP) analyzer.
Results: A total of 67.33%(1212/1800) of samples were
positive for at least one virus. The 1212 positive specimens
included 475 human rhinovirus(HRV),356 respiratory syncytial
virus (RSV),160 human adenovirus(HADV),117 human parain-
ﬂuenza 3(HPIV-3),96 human bocavirus (HBoV), 96 Inﬂuenza A
(including 39 swine H1N1,21 inﬂuenza virus H3N2,9 seasonal
H1N1,6 inﬂuenza virus H2N2 and 21 etc inﬂuenza A virus),60
human parainﬂuenza 4(HPIV-4), 33 human coronaviruses NL63
and 229E(HCoV-NL63/229E), 27 Inﬂuenza C(Inf C), 20 human
metapneumovirus (hMPV), 15 HCoV-HKU1/OC43, 12 Inf B, 9 HPIV-
1, 9 WU polyomaviruses(WUPyV) and 3 HPIV-2. Co-infection by at
least 2 of the viral pathogens under study was observed in 13.5%
cases (243/1800).
Conclusion: This is a rapid and simple assay that could be used
in clinical diagnosis as well as for the surveillance for the spread of
antibiotic resistance determinants in epidemiological studies.
http://dx.doi.org/10.1016/j.ijid.2014.03.1336
Table 1
Baseline Characteristics Virologic responders n=92 (mean) Switched Group n=53 (mean) P value
Gender (M/F) (n) 48/44 36/17 0.06
HAI 5,9 6,9 0.01
Fibrozis 2,2 2,6 0.01
ALT (U/L) 52,4 63,8 0.009
AST (U/L) 39,2 46,9 0.008
HBV DNA (IU/mL) 1.262.186 1.063.139 0.03
